Protein PDK4 Interacts with HMGCS2 to Facilitate High Glucoseinduced Myocardial Injuries

Wenliang Tan1, Huogeng Bao2, Ziming Liu1

  • 1Department of Cardiology, Jiangxi Provincial People's Hospital, the First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi 330006, P.R. China.

Abstract

Insights

Diabetic cardiomyopathy involves cardiac dysfunction. This study found that silencing PDK4 and Hmgcs2 proteins, which interact, improved heart function and reduced damage in high glucose conditions.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Disorders
  • Molecular Mechanisms of Disease

Background:

  • Diabetic cardiomyopathy (DCM) is a distinct cardiac dysfunction in diabetic patients.
  • Understanding the molecular underpinnings of DCM is crucial for developing targeted therapies.
  • High glucose (HG) exposure is a key factor contributing to myocardial damage in diabetes.

Purpose of the Study:

  • To investigate the interaction between PDK4 protein and Hmgcs2.
  • To elucidate the mechanism of this interaction in high glucose-induced myocardial damage.
  • To assess the therapeutic potential of targeting PDK4 and Hmgcs2 in DCM.

Main Methods:

  • Analyzed PDK4 and Hmgcs2 expression in diabetic rat myocardium and HG-incubated H9C2 cells via Western blot.
  • Assessed cardiac function and apoptosis in diabetic rats using echocardiography and TUNEL assays.
  • Evaluated in vitro effects on cardiomyocyte injury, including cell viability, LDH release, caspase activity, ROS, and MDA levels, with co-immunoprecipitation to confirm protein interaction.

Main Results:

  • PDK4 and Hmgcs2 were upregulated in diabetic rat myocardium.
  • PDK4 interacted with Hmgcs2, upregulating its expression in HG-induced H9C2 cells.
  • Silencing PDK4 or Hmgcs2 individually improved cardiac function, reduced apoptosis, and mitigated HG-induced cardiomyocyte injury; combined silencing showed enhanced benefits.

Conclusions:

  • PDK4 and Hmgcs2 interact to exacerbate high glucose-induced myocardial injury.
  • Silencing PDK4 and Hmgcs2 offers a potential therapeutic strategy for diabetic cardiomyopathy.
  • Targeting the PDK4-Hmgcs2 interaction may alleviate cardiac dysfunction in diabetic patients.